-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-3007 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-3007 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-3007 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ipilimumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ipilimumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Ipilimumab (Yervoy, Winglore) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zimberelimab in Cervical Cancer Drug Details: Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that belongs...
-
Product Insights
Leiomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Leiomyosarcoma - Drugs In Development, 2023’, provides an overview of the Leiomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nasopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nasopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Nasopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...